These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 21486975)

  • 81. Safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9-45 years: A randomized, double-blind, placebo-controlled phase 1 clinical trial.
    Li J; Shi LW; Yu BW; Huang LR; Zhou LY; Shi L; Jiang ZW; Xia JL; Wang XY; Li RC; Yuan L; Li YP; Li CG
    Vaccine; 2023 May; 41(19):3141-3149. PubMed ID: 37061370
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
    Hu YM; Guo M; Li CG; Chu K; He WG; Zhang J; Gu JX; Li J; Zhao H; Wu XH; Lin B; Lin ZJ; Yao XM; Li YF; Wei F; Huang Y; Su YY; Zhu FC; Huang SJ; Pan HR; Wu T; Zhang J; Xia NS
    Sci China Life Sci; 2020 Apr; 63(4):582-591. PubMed ID: 31231780
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a
    Gilca V; Sauvageau C; Panicker G; De Serres G; Schiller J; Ouakki M; Unger ER
    Hum Vaccin Immunother; 2019; 15(7-8):1980-1985. PubMed ID: 31017850
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
    Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
    Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.
    Heijstek MW; Scherpenisse M; Groot N; Tacke C; Schepp RM; Buisman AM; Berbers GA; van der Klis FR; Wulffraat NM
    Ann Rheum Dis; 2014 Aug; 73(8):1500-7. PubMed ID: 23723319
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
    Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
    Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
    Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant.
    Pedersen C; Petaja T; Strauss G; Rumke HC; Poder A; Richardus JH; Spiessens B; Descamps D; Hardt K; Lehtinen M; Dubin G;
    J Adolesc Health; 2007 Jun; 40(6):564-71. PubMed ID: 17531764
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
    Romanowski B; Schwarz TF; Ferguson LM; Ferguson M; Peters K; Dionne M; Schulze K; Ramjattan B; Hillemanns P; Behre U; Suryakiran P; Thomas F; Struyf F
    Hum Vaccin Immunother; 2014; 10(5):1155-65. PubMed ID: 24576907
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunogenicity and safety of the 9-valent HPV vaccine in men.
    Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
    Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
    Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
    Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
    Lamb F; Herweijer E; Ploner A; Uhnoo I; Sundström K; Sparén P; Arnheim-Dahlström L
    BMJ Open; 2017 Jun; 7(6):e015021. PubMed ID: 28600369
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA; Walter EB; Fairchok MP; Monto AS; Neuzil KM
    Pediatrics; 2005 Apr; 115(4):1039-47. PubMed ID: 15805382
    [TBL] [Abstract][Full Text] [Related]  

  • 96. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age.
    Kosalaraksa P; Mehlsen J; Vesikari T; Forstén A; Helm K; Van Damme P; Joura EA; Ciprero K; Maansson R; Luxembourg A; Sobanjo-ter Meulen A
    Pediatr Infect Dis J; 2015 Jun; 34(6):627-34. PubMed ID: 25831420
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
    Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
    JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
    [TBL] [Abstract][Full Text] [Related]  

  • 98. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial.
    Stratton P; Battiwalla M; Tian X; Abdelazim S; Baird K; Barrett AJ; Cantilena CR; Childs RW; DeJesus J; Fitzhugh C; Fowler D; Gea-Banacloche J; Gress RE; Hickstein D; Hsieh M; Ito S; Kemp TJ; Khachikyan I; Merideth MA; Pavletic SZ; Quint W; Schiffman M; Scrivani C; Shanis D; Shenoy AG; Struijk L; Tisdale JF; Wagner S; Williams KM; Yu Q; Wood LV; Pinto LA
    JAMA Oncol; 2020 May; 6(5):696-705. PubMed ID: 32105293
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
    Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.